

A collaborative Approach to Assessing the Promise of Innovative Technologies

POÉTIS: Processus optimisé d'évaluation des technologies innovantes en santé

2017 CADTH Symposium - Concurrent Session B5 (HTA Methods)

Geneviève Plamondon, M.Sc.

Professionnelle scientifique- innovation et évaluation

Direction des services de santé et de l'évaluation des technologies, INESSS

April 24th, 2017

**Institut national
d'excellence en santé
et en services sociaux**

Québec 

DISCLOSURE STATEMENT

I have no actual or potential conflict of interest in relation to this topic.

POÉTIS: AN ITERATIVE EVALUATION BASED ON THE LIFECYCLE OF INNOVATIVE TECHNOLOGIES

INESSS' mission: to promote clinical excellence and the efficient use of resources in the health and social services sector



There is a wish / need to accelerate the introduction of technologies with a proven or plausible added value for patients and the healthcare system




POÉTIS: a 4-phases process for evaluating innovative health technologies, characterized by the sustained involvement of stakeholders (including patients and clinicians)

*Institut national
d'excellence en santé
et en services sociaux*

Québec 

POÉTIS: AN ITERATIVE EVALUATION BASED ON THE LIFECYCLE OF INNOVATIVE TECHNOLOGIES



POÉTIS PHASE 1: OBJECTIVES

- To establish an early dialogue between stakeholders
- To assess the potential value (promise) of technologies for patients and the health system
- To assess the plausibility of the technologies' promise of value

- 
- Early dialogue between relevant stakeholders
 - Evaluation of the promise and its plausibility

1
R&D

IN ORDER TO:

- Foster the development of technologies aligned with the patients and health system's needs and likely to contribute to the economic development of the province (in collaboration with the Ministry of Economy, Science and Innovation)
- Contribute to the introduction of innovation in a rational and ethical way

*Institut national
d'excellence en santé
et en services sociaux*

Québec 

POÉTIS PHASE 1: MULTICRITERIA EVALUATION TOOL

| CATEGORY | CRITERIA |
|---|--|
| Contextual | <ul style="list-style-type: none"> • Disease severity • Size of the affected population • Health needs intended to fulfill |
| Claimed benefits for the patients | <ul style="list-style-type: none"> • Effectiveness • Security • Quality of life |
| Claimed benefits for the health system | <ul style="list-style-type: none"> • Organisational • Economic |
| Information supporting the promise | <ul style="list-style-type: none"> • Type of evidence • Quality of evidence |
| IF THE TECHNOLOGY IS PROMISING: | |
| Anticipated capacity of the health system to introduce the technology | <ul style="list-style-type: none"> • Requirements • Opportunity costs • Barriers |
| R&D process | <ul style="list-style-type: none"> • Identification and confirmation of patients' and health system's needs • Ongoing and future studies |

CONCLUDING REMARKS

- The collaboration between all stakeholders from the innovation field led to the development of the approach
- POÉTIS is still a work in progress: next steps
- We believe that assessing technologies early in their lifecycle will foster the development of technologies that better meet the needs of patients and the healthcare system
- And this will contribute to having the most valuable technologies available and used in a responsible way, for the greater benefit of patients and the population.

QUESTIONS?

THANK YOU for helping us promote clinical excellence and efficient use of resources in the health and social services sector.

*Institut national
d'excellence en santé
et en services sociaux*

Québec 

REFERENCES

- Axencia de Avaliacion de Tecnoloxias Sanitarias de Galicia (Avalia-t), "Priorisation tool, Observation." Retrieved November 21, 2016, from <http://www.pritectools.es/Controlador/Monitorizacion/monitorizacionAction.php?idHerramienta=1>.
- Evidem Collaboration, (2015). "Decision Criteria. Conceptual background, definitions, design & instructions." Retrieved November 11, 2016, from <https://www.evidem.org/docs/2016/EVIDEM-v3-1-Decision-criteria-conceptual-background-definitions-instructions-Oct-2015.pdf>.
- Eunethta. "HTA Core Model Version 3.0." Retrieved November 15, 2016, from <http://www.eunethta.eu/hta-core-model>.
- EuroScan. "A toolkit for the identification and assessment of new and emerging health technologies." Retrieved November 21, 2016, from <https://www.euroscan.org/methods/methods-toolkit/>.
- Government of United Kingdom, "Accelerated Access Review: Final Report." Retrieved November 11, 2016, from <https://www.gov.uk/government/organisations/accelerated-access-review>.
- Haute autorité de santé (HAS), (2016). "Circulaire Instruction forfait innovation." Retrieved November 11, 2016, from http://www.has-sante.fr/portail/jcms/c_2035788/fr/forfait-innovation.
- National Institute for Health and Clinical Excellence (NICE) (2011). "Medical Technologies Evaluation Programme: Methods Guide." Retrieved November 11, 2016, from <https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-medical-technologies-evaluation-programme>.
- Personal communication, Zanya Khayat, Director, MaRS EXCITE, December 21, 2016.
- Personal communication, Shonagh Ramsey, Project Officer, Scottish Health Technologies Group, November 17, 2016.